Mengni Guo, MD
Medical Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Guo’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A185883 · Current
Licensed to practise in California · since 2023 · expires 2027-06-30 · Peking Union Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$8,428
Pharmacies billed $8,428 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 62) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
48 generic and 14 brand-name prescriptions · $8,428 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Potassium Chloride | 11 | $111 | $10 |
| Prednisone | 11 | $30 | $3 |
Year by year
| 2024 | 62 | 20 | 0% (0) | 23% | $8,428 |
| 2023 | 191 | 44 | 0% (0) | None | $20,314 |
| 2022 | 258 | 69 | 0% (0) | None | $32,017 |
| 2021 | 186 | 54 | 0% (0) | None | $38,761 |
| 2020 | 52 | 20 | 0% (0) | None | $3,137 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Atorvastatin | 21 | $434 | $21 |
| Carvedilol | 14 | $288 | $21 |
| Levothyroxine | 14 | $118 | $8 |
2022: 3 drugs
| Diclofenac | 16 | $540 | $34 |
| Atorvastatin | 17 | $265 | $16 |
| Metformin | 12 | $128 | $11 |
2021: 1 drug
| Amlodipine Besylate | 18 | $90 | $5 |
Money from drug and device companies
$302 in 2025
| 2025 | 5 | 6 | None | $302 |
| 2024 | 6 | 10 | None | $560 |
| 2023 | 6 | 9 | None | $467 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Reblozyl | $115 | 1 payment
|
| Incyte | Monjuvi | $67 | 1 payment
|
| BeOne Medicines USA | Brukinsa | $55 | 2 payments
|
| Janssen Biotech | Talvey | $40 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $25 | 1 payment
|
See all 6 published payments
| BeOne Medicines USA | Meals · 2025-10-17 | Brukinsa | $19 |
| BeOne Medicines USA | Meals · 2025-09-18 | Brukinsa | $36 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-05 | Reblozyl | $115 |
| Regeneron Healthcare Solutions | Meals · 2025-03-03 | Libtayo | $25 |
| Janssen Biotech | Meals · 2025-02-26 | Talvey | $40 |
| Incyte | Meals · 2025-02-04 | Monjuvi | $67 |
See earlier years (2024, 2023)
2024: $560
| Pfizer | Adcetris | $167 | 3 payments
|
| Genzyme | Sarclisa | $125 | 1 payment
|
| Janssen Scientific Affairs | Tecvayli | $92 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $72 | 2 payments
|
| Janssen Biotech | Darzalex | $57 | 2 payments
|
| Lilly USA | None | $47 | 1 payment
|
2023: $467
| Astellas Pharma US | Xospata | $174 | 3 payments
|
| Kite Pharma | Yescarta | $116 | 1 payment
|
| Incyte | None | $83 | 1 payment
|
| Seagen | Adcetris | $52 | 2 payments
|
| Mirati Therapeutics | Krazati | $23 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $18 | 1 payment
|
Professional record
- NPI
- 1811525637
- Licence
- CA A185883California A185883: Current · expires 2027-06-30
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2020-03-28
- NPI last updated
- 2026-07-02
- NPI record certified
- 2026-07-02
This is when the NPI record was last certified, not a medical board exam.